A5066728112- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Bladder and Urothelial Cancer Treatments
- Renal and related cancers
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Cancer, Lipids, and Metabolism
- Urinary and Genital Oncology Studies
- Multiple and Secondary Primary Cancers
- Cancer Treatment and Pharmacology
- Medical Imaging and Pathology Studies
- Prostate Cancer Diagnosis and Treatment
- Bone health and treatments
- Colorectal Cancer Treatments and Studies
- Ferroptosis and cancer prognosis
- Testicular diseases and treatments
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Epigenetics and DNA Methylation
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer Research and Treatments
- Urologic and reproductive health conditions
Tel Aviv Sourasky Medical Center
2023-2025
Assaf Harofeh Medical Center
2012-2023
Tel Aviv University
1999-2020
Ghent University Hospital
2017
Mount Vernon Cancer Centre
2017
Institute of Cancer Research
2017
Comprehensive Cancer Center Vienna
2013
University of Szeged
2013
Medical University of Vienna
2013
Cleveland Clinic
2013
To evaluate the relative efficacy of cisplatin, cyclophosphamide, and Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) (CISCA) versus methotrexate, vinblastine, Adriamycin, cisplatin (MVAC), a prospective randomized trial was performed in patients with advanced metastatic urothelial tumors. Patients were stratified by histologic disease type degree tumor dissemination. Equal distribution clinical characteristics achieved. One hundred ten urinary tract (86 bladder, 16 renal pelvis,...
In advanced prostate cancer (APC), successful drug development as well advances in imaging and molecular characterisation have resulted multiple areas where there is lack of evidence or low level evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some these topics. To present the report APCCC 2017. Ten important controversy APC management were identified: high-risk localised locally cancer; “oligometastatic” castration-naïve castration-resistant role APC;...
Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. We evaluated the of cabozantinib in patients castration-resistant prostate cancer (CRPC) a phase II randomized discontinuation trial expansion cohort.Patients received 100 mg daily. Those stable disease per RECIST at 12 weeks were randomly assigned to or placebo. Primary end points objective response rate progression-free survival (PFS) after...
The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for ten most important areas of controversy in advanced prostate cancer (APC) management. successful registration several drugs castration-resistant recent studies chemo-hormonal therapy men with castration-naïve have led to considerable uncertainty as best treatment choices, sequence options appropriate patient selection. Management recommendations based on...
Forty-two cases of sarcomatoid renal cell carcinoma were reviewed clinicopathologically. Twenty-four patients men, and 18 women; average age was 56.2 years (range, 30-81 years). Eight, 9, 13, 12 Stages I, II, III, IV, respectively. Three morphologic patterns components identified: malignant fibrous histiocytomatous (26 cases), fibrosarcomatous (6 unclassified (10 cases). Mitotic count, degree pleomorphism, cellularity, amount tumor matrix in the areas, similar parameters carcinomatous...
BACKGROUND An every-2-week regimen of gemcitabine and paclitaxel was adapted for patients with advanced transitional cell carcinoma (TCC) who had received prior cisplatin-based chemotherapy. METHODS Forty-one or metastatic TCC systemic chemotherapy were treated an outpatient 2500–3000 mg/m2 150 every 2 weeks. RESULTS Forty 41 measurable disease. Response observed in 24 (60%; 95% confidence interval [CI], 45–75%). Eleven (28%) achieved complete response, 13 (33%) obtained partial response....
Seventy-one patients received adjuvant Cytoxan (cyclophosphamide; Bristol-Myers Co, Evansville, IN), Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (CISCA) chemotherapy between March 1981 1986. Patients CISCA if they had pathological findings that were thought to predict for high likelihood of relapse. These included the presence resected nodal metastases, extravesicular involvement tumor, lymphatic/vascular permeation primary or pelvic visceral invasion. Sixty-two...
A total of 21 patients with metastatic small cell carcinoma the prostate was treated combination chemotherapy, either following initial hormonal therapy (15) or as (6). Of 13 (62%) had pure carcinoma, whereas 8 (38%) mixed histology and adenocarcinoma. Patients presented a characteristic clinical picture large primary mass (16 cases) high frequency visceral metastases to liver (9), lungs (7) brain (2). The majority did not have an elevated serum specific antigen (1 14, 7%) prostatic acid...
Summary— Collecting duct carcinoma (CDC) is a recently recognised histological variety of renal (RC) considered to arise from the epithelium collecting ducts. Diagnosis this entity depends on well defined gross and microscopic criteria supported by characteristic immunostaining pattern. The clinical features these patients, natural course disease its response treatment have not been clearly established. Between 1980 1990 we treated 12 patients (median age 43 years, range 16–62) with kidney....
We retrospectively reviewed the genetic abnormalities detected clinically in 455 men with advanced germ cell tumors referred for chemotherapy. Of patients 49 had extragonadal and 406 testicular tumors. 19 mediastinal 4 (21 per cent, 3 teratocarcinoma 1 endodermal sinus tumor) Klinefelter's syndrome. Three of these a 47XXY 48XXYY karyotype. No syndrome was observed among 30 consecutive retroperitoneal or Karyotypes 35 testis cancer without evident congenital showed normal chromosomal...
No AccessJournal of Urology1 Nov 1991Combination Chemotherapy with Methotrexate, Bleomycin and Cisplatin for Advanced Squamous Cell Carcinoma the Male Genital Tract Francisco H. Dexeus, Christopher J. Logothetis, Avishay Sella, Robert Amato, Kilbourn, Karen Fitz, Anne Striegel DexeusFrancisco Dexeus , LogothetisChristopher Logothetis SellaAvishay Sella AmatoRobert Amato KilbournRobert Kilbourn FitzKaren Fitz StriegelAnne View All Author...
Thirty-two assessable patients with metastatic urothelial tumors refractory to standard chemotherapy methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) were treated escalated doses of MVAC plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Results this phase I trial revealed that (30 mg methotrexate/m 2 ,4 vinblastine/m , 60 doxorubicin/m 100 cisplatin/m ) can be tolerated by heavily pretreated patients. The side effects rhGM-CSF are...
Of 920 patients with histologically confirmed renal cell carcinoma (RCC) seen at University of Texas M. D. Anderson Hospital over a 10-year period, 44 (4.8%) had the sarcomatoid variant. The authors show that, although RCC has as common denominators classic in certain epidemiologic parameters such age and sex, its biologic behavior is different. It more malignant, higher metastatic rate, ultimate recurrence localized disease which translates to shorter survival time. Metastasis presentation,...
The neutrophil-to-lymphocyte ratio (NLR), an inflammation marker, is prognostic in several cancers. We assessed the association between pretreatment NLR and outcome of patients with metastatic castration-resistant prostate cancer (mCRPC) treated CYP17 inhibitor ketoconazole.This was international, retrospective study 156 mCRPC ketoconazole. independent effect factors associated treatment were determined by multivariate analysis.Seventy-eight (50%) had a ≥50% decline prostate-specific antigen...
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Feb 2002LOCAL ANESTHESIA FOR PROSTATE BIOPSY BY PERIPROSTATIC LIDOCAINE INJECTION: A DOUBLE-BLIND PLACEBO CONTROLLED STUDY DAN LEIBOVICI, AMNON ZISMAN, YORAM I. SIEGEL, AVISHAY SELLA, JUDY KLEINMANN, and ARIE LINDNER LEIBOVICIDAN LEIBOVICI , ZISMANAMNON ZISMAN SIEGELYORAM SIEGEL SELLAAVISHAY SELLA KLEINMANNJUDY KLEINMANN LINDNERARIE View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)69086-4AboutFull TextPDF...
PURPOSE A phase II clinical trial was performed to assess the antitumor activity and toxicity of ketoconazole in combination with doxorubicin (Adriamycin; Adria Laboratories, Columbus, OH) patients androgen-independent prostate cancer (AI PCa). PATIENTS AND METHODS Thirty-nine consecutive whose disease progressed following castration were treated oral (1,200 mg) daily Adriamycin (20 mg/m2 a 24-hour infusion) once weekly. Antitumor assessed by level prostatic-specific antigen (PSA) decline....
We reviewed retrospectively 97 patients treated with cisplatin, cyclophosphamide and doxorubicin chemotherapy at our hospital to evaluate predictive variables for response long-term survival free of disease. Histological subtype influenced response: 70 per cent the pure transitional cell carcinoma achieved an objective (partial remission 31 complete 39 cent), whereas 45 those mixed tumors 20 25 cent). Patients nodal metastases only had equal over-all rate visceral metastasis (64 versus 62...
Fifty patients with locally advanced or metastatic renal cell carcinoma were treated coumarin (1,2-benzopyrone) at 100 mg orally daily starting on day 1 and cimetidine 300 four times a 15. When disease progressed, was escalated to day. Three (6%; 95% confidence interval [Cl], 2% 17%) achieved partial response, one of those after dose escalation. In addition, patient had minor then progressing disease, again response All responders nonassessable primary tumors (three prior nephrectomy...
Obesity, smoking, hypertension, and diabetes are risk factors for renal cell carcinoma development. Their presence has been associated with a worse outcome in various cancers. We sought to determine their association of sunitinib treatment metastatic (mRCC).An international multicenter retrospective study sunitinib-treated mRCC patients was performed. Multivariate analyses were performed the between pretreatment status body mass index, diabetes, other known prognostic factors.Between 2004...